Colorectal Cancer

The implementation of a mailed stool test program increased colorectal cancer (CRC) screen-up-to-date rates compared with lower-intensity interventions, such as patient letters.

The FDA has approved fruquintinib (Fruzaqla) for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.

Caecal cancer and ascending colon cancer had slower rates of metastasis to main nodes compared with transverse colon cancer.

Postoperative circulating tumor DNA (ctDNA)–based minimal residual disease status demonstrated prognostic value for patients with stage 1 to 4 resected colorectal cancer, showing that those with positive ctDNA after surgery have significantly lower disease-free survival outcomes at 24 months vs those who were ctDNA negative.

Patients with colorectal cancer (CRC) can use C-reactive protein (CRP), lymphocyte to CRP ratio, and CRP to albumin ratio as markers for CRC prognosis.

Patients who underwent surgery for colorectal cancer had a higher risk of postoperative infection if they had high body mass index (BMI) or diabetes, among other risk factors.

The incidence of colorectal serrated lesions could be attributed to metabolic syndrome, which causes metabolic dysregulation.

The FDA has approved the CRCdx RAS Mutation Detection Kit as a companion diagnostic for panitumumab in the treatment of patients with metastatic colorectal cancer (mCRC), according to an announcement from EntroGen.

Experts in colorectal cancer (CRC) discussed the new health recommendations from the Network for Excellence in Health Innovations report and how they apply to the disparities in screening for CRC.

Significant increases in clinical staging for colorectal cancer were found when evaluating the extended timeframes beyond pre– and post–COVID-19 periods.

Patients who spoke Somali were more willing to get a screening for colorectal cancer (CRC) after a video intervention.

Successfully increasing colorectal cancer screening rates in African Americans could be achieved through the key roles of in-person interactions and community contexts.

Younger patients who had colorectal cancer (CRC) stoma had more symptom distress, were depressed and anxious, and had higher supportive care needs.

Sarcopenia or myosteatosis combined with low prediagnostic physical exercise was associated with increased mortality from colorectal cancer (CRC).

The integration of novel mRNA biomarkers into the ColoAlert screening test resulted in high sensitivity and specificity for detecting colorectal cancer (CRC).

Although nofazinlimab was well tolerated and showed antitumor activity in many tumor types, no response was found when combined with regorafenib to treat metastatic colorectal cancer (mCRC).

Screening for colorectal cancer (CRC) is defined by racial differences, which could be explained through social context.

Although mortality and disability-adjusted life-years remained stable, the prevalence and incidence of early-onset colorectal cancer (CRC) increased globally in individuals aged 40 to 49 years.

The FDA has granted 2 breakthrough therapy designations to trastuzumab deruxtecan for the treatment of patients with unresectable or metastatic HER2-positive solid tumors that have progressed after prior treatment and who have no satisfactory alternative treatment options, and for those with HER2-positive metastatic colorectal cancer who have received at least 2 prior lines of therapy.

A significant relationship between visceral obesity and anastomotic leakage was found, which indicates that visceral obesity could be a risk factor in surgery for colon cancer.

Circulating tumor DNA (ctDNA) status at the time of postoperative minimal residual disease assessment is a prognostic factor for disease-free survival (DFS) in patients with radically resected stage II to IV colorectal cancer (CRC).

Although HER2 amplification showed prognostic capabilities in patients with RAS wild-type metastatic colorectal cancer (mCRC), it was not predictive of survival benefit as a first-line treatment option in combination with panitumumab vs standard-of-care bevacizumab.

Three sessions of a semi-structured focus group were conducted to gain patient feedback on personalized screening for colorectal cancer (CRC).

Delays in time to treatment initiation may be associated with demographic and socioeconomic disparities, with care coordination, clinical, and socioeconomic factors representing potential predictors of time to treatment initiation.

Social determinants of health are associated with colonoscopy noncompletion in a Medicaid patient population at the Providence Community Health Centers.

Patients were twice as likely to get a colorectal cancer screening and 50% more likely to get a breast cancer screening in their first year of Medicare coverage.

Adults younger than 50 years with colorectal cancer (CRC) who experience postpresentation delays in treatment did not appear to have worse outcomes, according to a study in Ontario, Canada.

The FDA approved trifluridine and tipiracil (Lonsurf) plus bevacizumab (Avastin) for patients with metastatic colorectal cancer who had previously been treated based on data from the phase 3 SUNLIGHT trial.

A systematic, mixed methods “sludge audit” identified novel health system delivery targets for improving colorectal cancer screening services.

Under the agreement, Takeda will pay Hutchmed $400 million up front and up to $730 million in additional potential payments relating to regulatory, development, and commercial sales milestones, as well as royalties on worldwide net sales, with the exception of mainland China, Hong Kong, and Macau.